title: Oral pharmacokinetics and ascitic fluid penetration of ofloxacin in cirrhosis.
abstract: Plasma and ascitic fluid concentrations of ofloxacin were determined in 12 cirrhotic patients after a single dose and repeated 200 mg oral doses. The single dose kinetics were compared to those obtained in 12 healthy volunteers. Mean plasma elimination half-life was 11.6 h in cirrhotics and 7.0 h in controls. Mean total clearance was 2.3 times lower in patients than in controls, due to a significant decrease of renal clearance of the drug, unrelated to creatinine clearance. Mean apparent volume of distribution was 1.2 l/kg in patients and 1.8 l/kg in controls. Estimated by the ratio of AUC in peritoneal fluid and plasma, ascitic fluid penetration was 80% after the first oral dose. Ascitic fluid concentrations equaled corresponding plasma concentrations after 10 h, without pronounced accumulation of ofloxacin in ascites. We may conclude that, in cirrhotic patients with normal serum creatinine, a significant impairment of renal tubular handling of ofloxacin could be observed and led to a delayed elimination half-life of the drug. Because of its broad spectrum of activity, low side-effect profile, and large ascitic fluid penetration after oral administration, ofloxacin appears to be a new therapeutic approach of severe infections in cirrhotic patients, in particular spontaneous bacterial peritonitis.
authors.affiliation: Service d'Hépato-Gastroentérologie, C.H.U. Jean Bernard, Poitiers, France.
authors.forename: C
authors.initials: C
authors.lastname: Silvain
authors.forename: S
authors.initials: S
authors.lastname: Bouquet
authors.forename: J P
authors.initials: JP
authors.lastname: Breux
authors.forename: B
authors.initials: B
authors.lastname: Becq-Giraudon
authors.forename: M
authors.initials: M
authors.lastname: Beauchant
mesh_terms: D000284:Administration, Oral; D000328:Adult; D001202:Ascitic Fluid / Q000378:metabolism*; D004058:Diffusion; D005260:Female; D006801:Humans; D008104:Liver Cirrhosis, Alcoholic / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin / Q000008:administration & dosage / Q000493:pharmacokinetics*
chemical_list: D015242:Ofloxacin